KVUE — Kenvue Inc.

Sell-side consensus is a firm Hold (10 hold / 4 buy / 0 sell) with targets clustered at $19.00-$19.50 (FMP consensus $19.50 on just 2 contributors) that essentially mirror deal consideration rather than express a business view - a spread, not an opinion. Q2 2026 (reported 2026-08-06) was a narrow miss: adjusted EPS $0.31 vs $0.32 consensus and revenue $3.955B vs ~$3.97B expected, ending a four-quarter beat streak; adjusted gross margin compressed to 60.2% on inflation, FX and tariffs, and management gave no guidance or earnings call because of the pending deal. Shares fell 5.12% in the week and 6.32% in the month ending 2026-09-13, but because consideration includes a fixed ratio of Kimberly-Clark stock, that decline is far better explained by KMB's own weakness mechanically dragging KVUE than by independent deterioration - which is why the read is neutral, not bearish.

Revenue inflected modestly: after a -3.5% YoY Q3 2025 (3,764 vs 3,899), YoY growth turned positive at +3.2% (Q4 2025, 3,780 vs 3,662), +4.5% (Q1 2026, 3,909 vs 3,741) and +3.0% (Q2 2026, 3,955 vs 3,839) - but that is a shallow recovery off easy comps, and FY27E revenue of $15.605B is only ~1.3% above TTM revenue of $15.408B, so the run-rate is stalled rather than accelerating. Reported gross margin has drifted lower (58.2% in Q2 2026 vs 59.1% in Q2 2024, and 58.9% in Q2 2025), and the adjusted figure fell to 60.2%. GAAP operating margin has been volatile on one-offs but improved YoY (21.9% in Q1 2026 vs 14.9% in Q1 2025; 17.7% in Q2 2026 vs 18.0% in Q2 2025), and GAAP diluted EPS rose YoY for a fourth straight quarter ($0.24 vs $0.22) - though the adjusted number missed. TTM free cash flow of $1.839B (196+744+350+549) is up ~12.6% from $1.633B a year earlier, which is the healthiest line in the P&L. Net: a genuine but shallow earnings/FCF inflection that is now largely moot, with the newest quarter showing margin pressure rather than improvement.

As of 2026-09-13, KVUE at $17.78 traded on 20.4x TTM EPS of $0.864 and 15.1x FY27E EPS of $1.176 (PEG 1.16), with 3.24x book, 2.22x sales vs. a 5-year average of 2.84x, 13.1x EV/EBITDA, and a 4.39% yield per FMP (~4.7% on the declared $0.84 annualized rate). The deterministic model's 'Cheap vs. its own history' flag rests on a 5-year average P/E of 26.98 - I think that overstates the case, because that average was set in the post-spinoff period when the stock carried a scarcity premium that has since reset permanently. On absolute terms, 15.1x forward earnings for ~1.3% revenue growth, 8.8% ROIC and a 60.2% adjusted gross margin is fair, not cheap. The apparent discount to history is also partly the merger spread: the $17.78 price sits roughly 5-9% below the ~$19.00-$19.50 implied deal consideration, so what looks like an earnings valuation gap is really merger-arbitrage pricing.

Do not read KVUE as an earnings story. With consideration structured as fixed cash plus a fixed ratio of Kimberly-Clark stock, the large majority of KVUE's value now moves with KMB's share price - the 6.32% one-month decline into 2026-09-13 is best explained by that mechanical linkage, not by the one-cent adjusted EPS miss. That means there is no 'underpriced turnaround' trade available here: if the deal closes you become a KMB holder, and if it breaks, the standalone case is a roughly 1%-growth consumer health company that would likely de-rate from today's 15.1x forward to 13-14x, or roughly $15.50-$16.50. The question an investor actually needs to answer is whether they want to own Kimberly-Clark after close - not whether Neutrogena is about to reaccelerate.

As of 2026-09-13, RSI(14) was 31.61 - near but not yet at oversold - with price 5.53% below its 20-day SMA, 6.82% below its 50-day SMA, and only 1.15% below its 200-day. Returns were -5.12% over one week, -6.32% over one month, -1.98% over three months and +1.66% over six months: a short-term breakdown inside a wide $14.02-$20.13 52-week range, not a trend. For a stock whose price is tethered to a fixed exchange ratio, technicals carry little signal; the practical read is that the pullback modestly widened the arbitrage spread, but it did so because KMB fell, so it is not a bargain you are stepping into.

• Consumer staples cost and demand pressure: persistent input inflation, tariff costs and FX volatility are compressing adjusted gross margin (60.2% in Q2 2026), with cautious discretionary spending hitting skin health and beauty specifically.
• Rates and defensive rotation: a 0.43 beta and ~4.7% yield make KVUE a bond proxy, so it trades on rate expectations and staples-vs-growth rotation as much as on its own P&L.
• Antitrust and regulatory review: US, India and Australia clearances are secured, but remaining international reviews - notably the EU - gate the Q4 2026 close and can impose remedies or a Phase 2 delay.
• Kimberly-Clark's own equity: because part of the consideration is KMB stock, KMB's multiple, earnings trajectory and leverage outlook directly set KVUE's implied deal value.
• Post-close leverage and dividend arithmetic at the combined company: a ~$40B+ equity-value combination will carry meaningful debt, which will frame the future dividend policy and the multiple KVUE holders inherit.

• Final international regulatory clearances (notably the European Union) and confirmation of a Q4 2026 merger close - the single dominant driver; clearance tightens the spread, while a Phase 2 or remedy demand widens it and could push closing into 2027.
• Kimberly-Clark's quarterly results and share price: with cash-plus-stock consideration, KMB's equity moves KVUE's implied deal value directly, as it did over the month into 2026-09-13.
• Kenvue's Q3 2026 results (expected early November 2026), likely the last standalone print before close: watch adjusted gross margin versus the 60.2% Q2 level and whether the adjusted EPS miss was a blip or a trend.
• The October 2, 2026 dividend payment ($0.21 declared September 10, record date September 21) and any signal on the combined company's post-close dividend policy.
• Any deal-break or reverse-termination outcome, which would force the market to re-price KVUE on standalone fundamentals rather than on transaction terms.

• Deal break or delay: an EU Phase 2 investigation or remedy demand could push closing past Q4 2026, and an outright break would likely send shares to standalone value of roughly $15.50-$16.50 - a 10-15% hit from $17.78 - with the break itself probably signaling structural competitive concerns.
• Proxy exposure to Kimberly-Clark: the fixed stock component means KVUE can fall even when the deal looks certain, which is the most plausible cause of the 6.32% one-month decline into 2026-09-13.
• Fundamental erosion: Q2 2026 broke a four-quarter adjusted beat streak ($0.31 vs $0.32), adjusted gross margin fell to 60.2% on inflation/FX/tariffs, FY27E revenue growth is only ~1.3%, and ROIC of 8.8% is below what a high-quality staples compounder should earn.
• Thin balance-sheet and payout cushion: $7.07B long-term debt against $1.11B cash, a 1.005 current ratio and 0.712 quick ratio, with the $0.84 annualized dividend (~$1.61B) consuming roughly 88% of $1.839B TTM free cash flow.
• Opacity while the transaction is pending: no earnings call and no forward guidance means investors are underwriting regulatory headlines and KMB's equity rather than any direct business disclosure.

As of 2026-09-13, KVUE at $17.78 is not a consumer-health turnaround - it is a merger-arbitrage position offering roughly 6% upside to a probability-weighted fair value of $18.89 if the Kimberly-Clark deal closes on schedule in Q4 2026, against 10-15% downside if it breaks, plus a ~4.7% dividend while waiting. The underlying business is mediocre: ~1.3% expected revenue growth, 8.8% ROIC, a 60.2% adjusted gross margin under tariff and FX pressure, and a freshly broken adjusted-earnings beat streak, all of which make 15.1x forward earnings look fair rather than cheap. Own it only for the spread, and only if you are comfortable holding Kimberly-Clark shares afterward; as a buy-and-forget compounder it does not qualify. This is analysis, not personalized financial advice.

Probability-weighted merger-arbitrage valuation: 80% weight on an on-time Q4 2026 close at the ~$19.30 implied consideration (fixed cash plus KMB stock, consistent with the $19.00-$19.50 target/consideration cluster as of 2026-09-13), 12% on a delayed close worth ~$18.40 today, and 8% on a deal break worth ~$15.50 standalone (13.2x FY27E EPS of $1.176, a modest de-rating from the current 15.1x forward). That yields $18.89, or ~6% above the $17.78 price as of 2026-09-13; sensitizing break probability to 12% only moves the result to ~$18.75, so the estimate is robust.